Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H receptors, α-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.
May be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder).
Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.
Bezirkskrankenhaus Augsburg, Augsburg, Germany
Krankenhaus Hedwigshöhe, Berlin, Germany
Hannover Medical School, Hannover, Germany
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
National Health Insurance Corporation Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
Uijeongbu St.Marry's Hospital, Uijeongbu-si, Gyeonggi-do, Korea, Republic of
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
The Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Ewha University Mok-dong Hospital, Seoul, Korea, Republic of
Seoul St. Marry's Hospital, Seoul, Korea, Republic of
Institute of Psychiatry, Clinics Hospital, University of São Paulo Medical School, São Paulo, SP, Brazil
Institute of Psychiatry, Sao Paulo, SP, Brazil
Stanford University Medical Center, Stanford, California, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.